2026-04-18T02:09:29Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/118502025-10-24T10:32:40Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Nuñez-Conde, A. author Castella Fierro, Eva author Aceituno, Laia author Escolà-Vergé, Laura author Pigrau, Carlos author Len, Oscar author Falcó, Vicenç author VIÑADO, BELEN author Serra-Pladevall, Judit author 2024-08-21T07:38:26Z 2024-08-21T07:38:26Z 2024-06-10 Acute focal pyelonephritis; Quinolones; Urinary tract infections Pielonefritis focal aguda; Quinolones; Infeccions del tracte urinari Pielonefritis focal aguda; Quinolonas; Infecciones del tracto urinario Background Evidence regarding the best antibiotic regimen and the route of administration to treat acute focal bacterial nephritis (AFBN) is scarce. The aim of the present study was to compare the effectiveness of intravenous (IV) β-lactam antibiotics versus oral quinolones. Methods This is a retrospective single centre study of patients diagnosed with AFBN between January 2017 and December 2018 in Hospital Universitari Vall d’Hebron, Barcelona (Spain). Patients were identified from the diagnostic codifications database. Patients treated with oral quinolones were compared with those treated with IV β-lactam antibiotics. Therapeutic failure was defined as death, relapse, or evolution to abscess within the first 30 days. Results A total of 264 patients fulfilled the inclusion criteria. Of those, 103 patients (39%) received oral ciprofloxacin, and 70 (26.5%) IV β-lactam. The most common isolated microorganism was Escherichia coli (149, 73.8%) followed by Klebsiella pneumoniae (26, 12.9%). Mean duration of treatment was 21.3 days (SD 7.9). There were no statistical differences regarding therapeutic failure between oral quinolones and IV β-lactam treatment (6.6% vs. 8.7%, p = 0.6). Out of the 66 patients treated with intravenous antibiotics, 4 (6.1%) experienced an episode of phlebitis and 1 patient (1.5%) an episode of catheter-related bacteraemia. Conclusions When susceptible, treatment of AFBN with oral quinolones is as effective as IV β-lactam treatment with fewer adverse events. Open Access Funding provided by Universitat Autonoma de Barcelona. http://hdl.handle.net/11351/11850 Avaluació de resultats (Assistència sanitària) Malalties bacterianes - Tractament Medicaments antibacterians - Ús terapèutic CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Anti-Bacterial Agents Other subheadings::Other subheadings::/therapeutic use DISEASES::Bacterial Infections and Mycoses::Bacterial Infections Other subheadings::Other subheadings::Other subheadings::/drug therapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antibacterianos Otros calificadores::Otros calificadores::/uso terapéutico ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento Oral quinolones versus intravenous β-lactam for the treatment of acute focal bacterial nephritis: a retrospective cohort study